Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial) (NCT00119457) | Clinical Trial Compass
CompletedPhase 2
Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
Czechia300 participantsStarted 2005-01
Plain-language summary
The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Must have undergone reparative surgery within 72 hours after unilateral hip fracture, defined as fracture of the upper third of either femur
* Must have started standard prophylactic treatment for VTE with low molecular weight heparin (LMWH) or heparin before surgery or within 24 hours after hip fracture surgery, and continued treatment with LMWH or heparin for at least five days, but not more than nine days, after surgery
* Last dose of LMWH or heparin must have been administered at least 12 hours, but not more than 48 hours, before dosing with study drug
* Females must have a negative serum pregnancy test
* Must weigh at least 45 kg
* Must demonstrate the mental and physical ability and willingness to follow all study-specific instructions
* Must be able to read, comprehend and sign the Ethics Committee-approved informed consent form
Exclusion Criteria:
* Evidence of active bleeding
* Clinical signs of VTE
* Any medical requirement for (or intention to use) continued anticoagulation after randomization through the end of study
* History of intracranial bleeding, hemorrhagic stroke, or gastrointestinal bleeding within 3 months of study start
* Presence of active malignant disease
* Hip fracture associated with multiple trauma, that places patient at excessive risk for hemorrhage or organ system failure, or that may make it difficult or impossible to perform bilateral lower limb venography
* Intention to take aspirin at doses greater than 325 mg/day
*…
What they're measuring
1
To evaluate the antithrombotic efficacy of TTP889, administered once daily for three weeks, in patients who have completed standard prophylactic treatment for deep vein thrombosis after hip fracture surgery.
2
Evaluation of safety of once daily oral administration of TTP889 for three weeks